Skip to main navigation Skip to search Skip to main content

Efectividad y seguridad de los nuevos tratamientos para la psoriasis moderada- grave en la práctica clínica real

Student thesis: Doctoral thesis

Abstract

Physicians must evaluate the results of pivotal trials together with real-world data on effectiveness and safety when making clinical decisions. _x000D_ The objective was to evaluate the safety and effectiveness of new drugs for the treatment of moderate to severe psoriasis in clinical practice. The research comprised three retrospective, observational, multicentre studies. The first evaluated the effectiveness and safety of ustekinumab 90 mg at week 24 in a group of patients weighing ≤100kg. The other two evaluated the effectiveness and safety of apremilast at 52 weeks and guselkumab at 24 weeks._x000D_ The first study analysed data from 74 patients. Mean (SD) score on the Psoriasis Area and Severity Index (PASI) was 7.9 (4.8) at baseline, 3.3 (3.5) at week 16, and 2.2 (2.4) at week 24. By week 24, 69.7% of the patients had an absolute PASI score under 3, 56.1% presented a PASI 75 response (at least 75% reduction from baseline), and 31.8% a PASI 90 response. A body mass index corresponding to overweight or obesity was not associated with any significant differences (p = 0.995). In the group of patients who had presented an inadequate response to prior treatment with UST 45 mg, the mean PASI was 2.7 (2.6) at week 24, and 63% of the patients had a PASI score under 3. Analysis of the safety data did not reveal any serious adverse events (AE)._x000D_ The study of guselkumab analysed data from 343 patients. By week 24, the mean PASI score had fallen from 11.1 (7.3) to 1.7 (2.8); 85.9% of patients had a PASI of 4 or less and 77.9% a PASI of 2 or less. In terms of relative improvement, 59.4% of the patients studied achieved a PASI 90 response and 49.0% a PASI 100 response. On multivariate analysis, a BMI of 30 or less (OR, 0.44; 95% CI, 0.22-0.88) and greater prior exposure to biologic therapy (OR, 0.69; 95% CI, 0.56-0.84) reduced the moderate probability of the patient achieving a PASI score of 2 or less at 24 weeks. AE were rare (9.9%) and had led to withdrawal of treatment in only 9 patients (2.6%) _x000D_ The apremilast cohort included a total of 292 patients with plaque psoriasis and 85 with palmoplantar psoriasis. In the patients with plaque psoriasis, mean PASI was 10.7 (7.0) at baseline decreasing to 3.0 (4.2) at 52 weeks. After 12 months of treatment, 73.6% of the patients had a PASI score of 3 or less. In terms of relative improvement, 49.7% achieved PASI 75 and 26.5% PASI 90 at week 52. In the group with palmoplantar psoriasis, the mean physician global assessment (PGA) score fell from 4.2 (5.2) at baseline to 1.3 (1.3) at week 52. Drug survival was 54.9% at 12 months. The main reasons for discontinuing treatment were loss of efficacy (23.9%) and AE (15.9%). In this series, 47% of the patients experienced AE, with the most common being gastrointestinal effects. _x000D_ The studies reported in this thesis are an accurate, contemporary, and real-time reflection of the results of the revolution in the treatment of psoriasis and represent the largest published series for each of the drugs studied. These studies highlight two fundamental differences between pivotal trials and real-world practice. The first is the use of endpoints reflecting relative clinical improvement in RCTs as against the use of the absolute PASI score to measure treatment outcomes in clinical practice. The second difference is the greater complexity of the patient profile in real-world clinical practice. With respect to safety, analysis of the data from routine clinical practice evidences the frequency of AE and the tolerability of the different treatments.
Date of Award21 Dec 2022
Original languageSpanish
SupervisorManuel Carrascosa Carrillo (Director)

Cite this

'